Metabasis Therapeutics, Inc.

Sankyo Company, Limited

M Rami Reddy

Mark D Erion

Qun Dang

K Raja Reddy

Srinivas Rao Kasibhatla

Gerard Robert Scarlato

Edward D Robinson

Atul Agarwal

Atul Agurwal

Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors. 

Purine inhibitors of fructose-1,6-bisphosphatase

Novel purine compounds of the Formula 1, pharmacuetically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors

Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase

Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described

Benzimidazole inhibitors of fructose 1,6-bisphosphatase

The present invention is directed towards novel azaindole compounds which bind to the AMP site and are potent FBPase inhibitors. The present invention also is directed towards the clinical use of the novel FBPase inhibitors as a method of treatment or prevention of diseases responsive to lowered blood glucose levels.

Indole and azaindole inhibitors of Fructose-1,6-biphosphatase

Novel purine compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described.

Purine inhibitors of fructose 1,6-bisphosphatase

Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described ##STR1##

Novel indole and azaindole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described: ##STR1## and pharmaceutically acceptable prodrugs and salts thereof.

Growing community of inventors

San Diego, CA, United States of America

M Rami Reddy